ReviewClinical ophthalmology (Auckland, N.Z.)2016
Neurofibromatosis: an update of ophthalmic characteristics and applications of optical coherence tomography.
Review in Clinical ophthalmology (Auckland, N.Z.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 54 citations in OpenAlex.
- The Complexities of Periorbital Neurofibroma: Diagnostic Ambiguity and Therapeutic Dilemmas: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2026Article
- In vivo analysis of iridocorneal angle parameters with spectral-domain optical coherence tomography in children with Neurofibromatosis type 1.Eye (London, England) · 2025Article
- Ocular manifestations in pediatric tumor suppressor gene mutations: a case series and literature review of RB1, NF1, NF2, VHL, and TSC.BMC pediatrics · 2025Review
- Genetics and current research models of Mendelian tumor predisposition syndromes with ocular involvement.Progress in retinal and eye research · 2025Review
- Neurofibromatosis.Advances in experimental medicine and biology · 2025Article
- Inner retinal layer thickness alterations in adult and pediatric patients with neurofibromatosis 1.Scientific reports · 2024Article
- Pathological findings in enucleated eyes of patients with neurofibromatosis type 1: report of a case with 15-year follow-up and review of 14 patients in the literature.BMC ophthalmology · 2024Review
- Neurofibromatosis Type 1-Retinal Alterations Detectable with Optical Coherence Tomography Angiography.Diagnostics (Basel, Switzerland) · 2024Article
- Secondary childhood glaucoma in neurofibromatosis type 1: an unusual corneal leukoma case report.Frontiers in oncology · 2024Article
- Choroidal Hyperreflective Nodules Detected by Infrared Reflectance Images Are a Diagnostic Criterion for Neurofibromatosis Type 1 Patients Excluding Those with High Myopia.Diagnostics (Basel, Switzerland) · 2023Article
- Time-Serial Evaluation of the Development and Treatment of Myopia in Mice Eyes Using OCT and ZEMAX.Diagnostics (Basel, Switzerland) · 2023Article
- Burden Among Caregivers of Pediatric Patients with Neurofibromatosis Type 1 (NF1) and Plexiform Neurofibroma (PN) in the United States: A Cross-Sectional Study.Neurology and therapy · 2022Article
- Clinical and humanistic burden among pediatric patients with neurofibromatosis type 1 and plexiform neurofibroma in the USA.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2022Article
- Anterior segment dysgenesis: Insights into the genetics and pathogenesis.Indian journal of ophthalmology · 2022Review
- Choroidal ganglioneuromas in Francois variant neurofibromatosis-1: A rare retinoblastoma mimic.Indian journal of ophthalmology · 2022Article
- Prevalence of Choroidal Abnormalities and Lisch Nodules in Children Meeting Clinical and Molecular Diagnosis of Neurofibromatosis Type 1.Translational vision science & technology · 2022Observational
- Ocular Neurofibromatosis.Cureus · 2021Article
- Corneal endothelial cells and central corneal thickness in patients with neurofibromatosis type 1.Indian journal of ophthalmology · 2021Article
- Case Report: Chemotherapy Indication in a Case of Neurofibromatosis Type 1 Presenting Optic Pathway Glioma: A One-Year Clinical Case Study Using Differential Tractography Approach.Frontiers in human neuroscience · 2021Article
- Optic Nerve Tortuosity in Neurofibromatosis Type 1: A Rare Case Report.Neuro-ophthalmology (Aeolus Press) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurofibromatosis (NF) is a multisystem disorder and tumor predisposition syndrome caused by genetic mutation on chromosome 17-17q11.2 in NF type 1 (NF1), and on chromosome 22-22q12.2 in NF type 2. The disorder is characterized by considerable heterogeneity of clinical expression. NF1 is the form with the most characteristic ocular manifestations. Lisch nodules of the iris are among the well-known diagnostic criteria for the disease. Glaucoma and associated globe enlargement have been described in a significant proportion of patients with NF1 and orbital-facial involvement. Optic nerve glioma may cause strabismus and proptosis, and palpebral neurofibroma may reach considerable size and occasionally show malignant transformation. Near infrared reflectance has greatly contributed to enhancing our knowledge on choroidal alterations in NF1. Indeed, some authors have proposed to include these among the diagnostic criteria. Optical coherence tomography has given new insight on retinal alterations and is a noninvasive tool in the management of optic nerve gliomas in children. Ocular manifestations in NF type 2 can range from early-onset cataracts in up to 80% of cases to optic nerve hamartomas and combined pigment epithelial and retinal hamartomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.